Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for ulcerative colitis: Long-Term safety of oral drug tested

NCT ID NCT02531126

Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety and effectiveness of an oral medication called RPC1063 for people with moderate to severe ulcerative colitis. It included 877 adults who had already taken part in earlier RPC1063 trials. The goal was to see how well the drug controls the disease over time and what side effects might occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

877 people

The number who actually took part.

Started

Dec 2015

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com Inclusion Criteria: • Previously participated in a trial of RPC1063 and meets the criteria for participation in the open-label extension as outlined in the prior trial Exclusion Criteria: * Receiving treatment with breast cancer resistance protein inhibitors * Clinically relevant cardiovascular conditions * Liver function impairment Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ulcerative colitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ulcerative colitis

Contacts and locations

Locations

  • Local Institution - 102

    Anaheim, California, 92801, United States

  • Local Institution - 112

    Oak Lawn, Illinois, 60453, United States

  • Local Institution - 117

    Mission Hills, California, 91345, United States

  • Local Institution - 119

    Baton Rouge, Louisiana, 70809, United States

  • Local Institution - 122

    Dallas, Texas, 75246, United States

  • Local Institution - 127

    Jacksonville, North Carolina, 28546, United States

  • Local Institution - 143

    Portland, Oregon, 97239, United States

  • Local Institution - 144

    Tucson, Arizona, 85712, United States

  • Local Institution - 152

    Camperdown, New South Wales, 2050, Australia

  • Local Institution - 179

    Germantown, Tennessee, 38138, United States

  • Local Institution - 236

    London, GREATER LONDON, E11 1NR, United Kingdom

  • Local Institution - 243

    London, SE1 9RT, United Kingdom

  • Local Institution - 264

    Lindsay, Ontario, K9V 5G6, Canada

  • Local Institution - 290

    Oklahoma City, Oklahoma, 73112, United States

  • Local Institution - 337

    Prague, 14021, Czechia

  • Local Institution - 342

    Klatovy, 399 01, Czechia

  • Local Institution - 354

    Wŏnju, 26426, South Korea

  • Local Institution - 364

    Seongnam-si, 13620, South Korea

  • Local Institution - 425

    Kłodzko, 57-300, Poland

  • Local Institution - 450

    Sofia, 1233, Bulgaria

  • Local Institution - 451

    Sofia, 1606, Bulgaria

  • Local Institution - 459

    Sofia, 1336, Bulgaria

  • Local Institution - 505

    Rehovot, 76100, Israel

  • Local Institution - 525

    Berlin, 13353, Germany

  • Local Institution - 535

    Berlin, 12200, Germany

  • Local Institution - 545

    Frankfurt, 60594, Germany

  • Local Institution - 567

    Florence, Tuscany, 50134, Italy

  • Local Institution - 600

    Ghent, 9000, Belgium

  • Local Institution - 601

    Leuven, 3000, Belgium

  • Local Institution - 611

    Osijek, 31000, Croatia

  • Local Institution - 643

    Athens, 10676, Greece

  • Local Institution - 658

    Chisinau, MD-2068, Moldova

  • Local Institution - 659

    Chisinau, MD2025, Moldova

  • Local Institution - 673

    Bucharest, 050098, Romania

  • Local Institution - 677

    Bucharest, 010719, Romania

  • Local Institution - 751

    Vitebsk, 210037, Belarus

  • Local Institution - 808

    Debrecen, 4032, Hungary

  • Local Institution - 816

    Balatonfüred, 8230, Hungary

  • Local Institution - 910

    Bardejov, 08501, Slovakia

  • Local Institution - 954

    Kharkiv, 61039, Ukraine

  • Local Institution - 957

    Vinnytsia, 21018, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.